Medical Developments International (MVP.AX) Stock Price

Medical Developments International Price

ASX·CLOSED
0.48AUD+0.02 (+4.26 %)
Market closed

Over the last 17 years Medical Developments International grew revenue by 8.9% annually, reaching 39.06 M AUD. Earnings per share have declined at 15.8% per year over the last 17 years. For Medical Developments International, the net margin of 0.2% is up versus -49.6% a few years ago. At today's price the dividend yield works out to roughly 5.75%. The payout ratio is around 476% of earnings. The consensus 12-month price target for Medical Developments International is 0.86 AUD, about 78.5% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 30% above its 52-week low.

Medical Developments International stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Medical Developments International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medical Developments International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medical Developments International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medical Developments International Stock Price History
DateMedical Developments International Price
8/5/20260.48 AUD
8/4/20260.46 AUD
8/3/20260.43 AUD
7/31/20260.46 AUD
7/30/20260.44 AUD
7/29/20260.46 AUD
7/28/20260.45 AUD
7/27/20260.50 AUD
7/24/20260.50 AUD
7/23/20260.39 AUD
7/22/20260.38 AUD
7/21/20260.39 AUD
7/20/20260.39 AUD
7/17/20260.41 AUD
7/16/20260.41 AUD
7/15/20260.41 AUD
7/14/20260.41 AUD
7/13/20260.41 AUD
7/10/20260.41 AUD
7/9/20260.41 AUD
7/8/20260.44 AUD
7/7/20260.41 AUD
7/6/20260.43 AUD
7/3/20260.41 AUD
7/2/20260.44 AUD
7/1/20260.41 AUD
6/30/20260.40 AUD
6/29/20260.38 AUD
6/26/20260.39 AUD
6/25/20260.38 AUD
6/24/20260.41 AUD
6/23/20260.40 AUD
6/22/20260.41 AUD
6/19/20260.41 AUD
6/18/20260.38 AUD
6/17/20260.38 AUD
6/16/20260.38 AUD
6/15/20260.38 AUD
6/12/20260.38 AUD
6/11/20260.38 AUD
6/10/20260.39 AUD
6/9/20260.40 AUD
6/5/20260.38 AUD
6/4/20260.38 AUD
6/3/20260.39 AUD
6/2/20260.38 AUD
6/1/20260.38 AUD
5/29/20260.38 AUD
5/28/20260.39 AUD
5/27/20260.40 AUD
5/26/20260.40 AUD
5/25/20260.40 AUD
5/22/20260.41 AUD
5/21/20260.40 AUD
5/20/20260.40 AUD
5/19/20260.41 AUD
5/18/20260.42 AUD
5/15/20260.43 AUD
5/14/20260.43 AUD
5/13/20260.44 AUD
5/12/20260.44 AUD
5/11/20260.44 AUD
5/8/20260.44 AUD
5/7/20260.44 AUD
5/6/20260.47 AUD
5/5/20260.46 AUD
5/4/20260.46 AUD
5/1/20260.47 AUD
4/30/20260.44 AUD
4/29/20260.46 AUD
4/28/20260.44 AUD
4/27/20260.48 AUD
4/24/20260.52 AUD
4/23/20260.38 AUD
4/22/20260.38 AUD
4/21/20260.38 AUD
4/20/20260.38 AUD
4/17/20260.38 AUD
4/16/20260.40 AUD
4/15/20260.38 AUD
4/14/20260.39 AUD
4/13/20260.40 AUD
4/10/20260.41 AUD
4/9/20260.43 AUD
4/8/20260.43 AUD
4/7/20260.41 AUD
4/2/20260.41 AUD
4/1/20260.39 AUD
3/31/20260.39 AUD
3/30/20260.37 AUD
3/27/20260.39 AUD
3/26/20260.39 AUD
3/25/20260.38 AUD
3/24/20260.38 AUD
3/23/20260.38 AUD
3/20/20260.41 AUD
3/19/20260.40 AUD
3/18/20260.39 AUD
3/17/20260.38 AUD
3/16/20260.41 AUD
3/13/20260.41 AUD
3/12/20260.41 AUD
3/11/20260.40 AUD
3/10/20260.40 AUD
3/9/20260.42 AUD
3/6/20260.43 AUD
3/5/20260.43 AUD
3/4/20260.44 AUD
3/3/20260.43 AUD
3/2/20260.44 AUD
2/27/20260.44 AUD
2/26/20260.43 AUD
2/25/20260.46 AUD
2/24/20260.45 AUD
2/23/20260.45 AUD
2/20/20260.47 AUD
2/19/20260.46 AUD
2/18/20260.46 AUD
2/17/20260.44 AUD
2/16/20260.45 AUD
2/13/20260.46 AUD
2/12/20260.47 AUD
2/11/20260.46 AUD
2/10/20260.47 AUD
2/9/20260.47 AUD
2/6/20260.45 AUD
2/5/20260.46 AUD
2/4/20260.49 AUD
2/3/20260.49 AUD
2/2/20260.46 AUD
1/30/20260.47 AUD
1/29/20260.48 AUD
1/28/20260.49 AUD
1/27/20260.49 AUD
1/23/20260.50 AUD
1/22/20260.51 AUD
1/21/20260.51 AUD
1/20/20260.55 AUD
1/19/20260.56 AUD
1/16/20260.55 AUD
1/15/20260.55 AUD
1/14/20260.56 AUD
1/13/20260.57 AUD
1/12/20260.55 AUD
1/9/20260.56 AUD
1/8/20260.55 AUD
1/7/20260.55 AUD
1/6/20260.56 AUD
1/5/20260.55 AUD
1/2/20260.55 AUD
12/31/20250.56 AUD
12/30/20250.56 AUD
12/29/20250.54 AUD
12/24/20250.52 AUD
12/23/20250.54 AUD
12/22/20250.52 AUD
12/19/20250.54 AUD
12/18/20250.51 AUD
12/17/20250.52 AUD
12/16/20250.52 AUD
12/15/20250.52 AUD
12/12/20250.55 AUD
12/11/20250.52 AUD
12/10/20250.54 AUD
12/9/20250.54 AUD
12/8/20250.52 AUD
12/5/20250.55 AUD
12/4/20250.52 AUD
12/3/20250.50 AUD
12/2/20250.50 AUD
12/1/20250.51 AUD
11/28/20250.52 AUD
11/27/20250.50 AUD
11/26/20250.50 AUD
11/25/20250.50 AUD
11/24/20250.51 AUD
11/21/20250.51 AUD
11/20/20250.54 AUD
11/19/20250.51 AUD
11/18/20250.51 AUD
11/17/20250.56 AUD
11/14/20250.56 AUD
11/13/20250.58 AUD
11/12/20250.56 AUD
11/11/20250.56 AUD
11/10/20250.58 AUD
11/7/20250.62 AUD
11/6/20250.65 AUD
11/5/20250.67 AUD
11/4/20250.69 AUD
11/3/20250.69 AUD
10/31/20250.70 AUD
10/30/20250.69 AUD
10/29/20250.69 AUD
10/28/20250.71 AUD
10/27/20250.68 AUD
10/24/20250.70 AUD
10/23/20250.75 AUD
10/22/20250.70 AUD
10/21/20250.71 AUD
10/20/20250.70 AUD
10/17/20250.71 AUD
10/16/20250.72 AUD
10/15/20250.76 AUD
10/14/20250.72 AUD
10/13/20250.73 AUD
10/10/20250.67 AUD
10/9/20250.63 AUD
10/8/20250.64 AUD
10/7/20250.61 AUD
10/6/20250.65 AUD
10/3/20250.65 AUD
10/2/20250.68 AUD
10/1/20250.68 AUD
9/30/20250.71 AUD
9/29/20250.70 AUD
9/26/20250.68 AUD
9/25/20250.67 AUD
9/24/20250.66 AUD
9/23/20250.66 AUD
9/22/20250.68 AUD
9/19/20250.70 AUD
9/18/20250.68 AUD
9/17/20250.68 AUD
9/16/20250.63 AUD
9/15/20250.60 AUD
9/12/20250.59 AUD
9/11/20250.59 AUD
9/10/20250.57 AUD
9/9/20250.58 AUD
9/8/20250.57 AUD
9/5/20250.57 AUD
9/4/20250.58 AUD
9/3/20250.58 AUD
9/2/20250.59 AUD
9/1/20250.57 AUD
8/29/20250.58 AUD
8/28/20250.58 AUD
8/27/20250.62 AUD
8/26/20250.63 AUD
8/25/20250.63 AUD
8/22/20250.62 AUD
8/21/20250.62 AUD
8/20/20250.63 AUD
8/19/20250.69 AUD
8/18/20250.67 AUD
8/15/20250.67 AUD
8/14/20250.71 AUD
8/13/20250.73 AUD
8/12/20250.74 AUD
8/11/20250.71 AUD
8/8/20250.71 AUD
8/7/20250.73 AUD
Access this data via the Eulerpool API
Get Free API Key

Medical Developments International Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
21.94 M AUD
-15.70 M AUD
-12.41 M AUD
Jan 1, 2023
32.34 M AUD
-20.27 M AUD
-5.61 M AUD
Jan 1, 2024
33.15 M AUD
-16.87 M AUD
-40.99 M AUD
Jan 1, 2025
39.06 M AUD
-1.76 M AUD
94,000.00 AUD
Jan 1, 2026 (e)
46.46 M AUD
2.32 M AUD
-2.04 M AUD
Jan 1, 2027 (e)
50.50 M AUD
-808,000.00 AUD
-566,394.30 AUD
Jan 1, 2028 (e)
55.45 M AUD
1.01 M AUD
4.26 M AUD
Jan 1, 2029 (e)
57.46 M AUD
7.05 M AUD
10.77 M AUD

Medical Developments International Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 1:02 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
9.0011.0015.0018.0017.0021.0022.0025.0021.0032.0033.0039.0046.0050.0055.0057.00
-18.1822.2236.3620.00-5.5623.534.7613.64-16.0052.383.1318.1817.958.7010.003.64
66.6772.7373.3366.6770.5966.6768.1876.0071.4368.7572.7374.3674.3674.3674.3674.36
6.008.0011.0012.0012.0014.0015.0019.0015.0022.0024.0029.0034.2137.1840.9042.38
–2.002.002.00–1.00–-5.00-15.00-20.00-16.00-1.002.00–1.007.00
–18.1813.3311.11–4.76–-20.00-71.43-62.50-48.48-2.564.35–1.8212.28
–1.001.001.00–1.00–-12.00-12.00-5.00-40.00–-2.00–4.0010.00
–––––––––-58.33700.00––––150.00
0.06–0.060.060.060.060.03–––––0.050.050.05–
-14.29–––––-50.00–––––––––
57.6457.7359.0859.6660.0466.0166.9771.4273.1786.5288.60112.16112.16112.16112.16112.16
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medical Developments International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medical Developments International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medical Developments International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medical Developments International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medical Developments International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medical Developments International stock margins

The Medical Developments International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medical Developments International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medical Developments International.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
75.64 %
-23.29 %
-49.58 %
Jan 1, 2022
69.31 %
-71.53 %
-56.54 %
Jan 1, 2023
68.69 %
-62.69 %
-17.35 %
Jan 1, 2024
73.50 %
-50.88 %
-123.66 %
Jan 1, 2025
75.35 %
-4.51 %
0.24 %
Jan 1, 2026 (e)
75.35 %
5.00 %
-4.39 %
Jan 1, 2027 (e)
75.35 %
-1.60 %
-1.12 %
Jan 1, 2028 (e)
75.35 %
1.82 %
7.68 %

Medical Developments International Stock Revenue, EBIT, Earnings per Share

The Medical Developments International earnings per share therefore indicates how much revenue Medical Developments International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.35 AUD
-0.08 AUD
-0.18 AUD
Jan 1, 2022
0.30 AUD
-0.21 AUD
-0.17 AUD
Jan 1, 2023
0.37 AUD
-0.23 AUD
-0.06 AUD
Jan 1, 2024
0.37 AUD
-0.19 AUD
-0.46 AUD
Jan 1, 2025
0.35 AUD
-0.02 AUD
0.00 AUD
Jan 1, 2026 (e)
0.41 AUD
0.02 AUD
-0.02 AUD
Jan 1, 2027 (e)
0.45 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2028 (e)
0.49 AUD
0.01 AUD
0.04 AUD

Medical Developments International business model & stock analysis

Medical Developments International Ltd is an Australian company specializing in the development and production of medical devices and products. The company was founded in 1971 by renowned researcher and entrepreneur Mark Sullivan and has since received numerous awards and accolades. The company's business model is based on the manufacture of emergency medical devices and products of the highest quality and effectiveness. It has three main business segments: Pharmaceuticals, Medical devices, and Animal health.

Medical Developments International SWOT Analysis

Strengths

Medical Developments International Ltd possesses several strengths that contribute to its success. These include:

  • Strong product portfolio: The company offers a wide range of innovative medical solutions.
  • Strong brand recognition: Medical Developments International Ltd is well-established and recognized in the healthcare industry.
  • Strong distribution network: The company has a robust distribution network, allowing for effective market reach.
  • Efficient research and development: The company invests in cutting-edge research and development, leading to continuous product innovation.

Weaknesses

Medical Developments International Ltd also faces certain weaknesses that pose challenges to its growth and sustainability:

  • Dependency on a limited product range: The company's success heavily relies on a few core products, limiting diversification opportunities.
  • Relatively small market presence: Compared to some competitors, Medical Developments International Ltd has a smaller market share.
  • Dependency on key suppliers: The company may face risks if it experiences disruptions in its supply chain.

Opportunities

Despite the weaknesses, Medical Developments International Ltd can capitalize on various opportunities in the healthcare market:

  • Increasing demand for medical solutions: The growing global population and rising healthcare needs present a vast opportunity for the company to expand its customer base.
  • Expansion into new markets: The company can explore untapped markets or regions with underdeveloped healthcare infrastructure.
  • Technological advancements: Medical Developments International Ltd can leverage advancements in technology to develop more advanced and efficient medical solutions.

Threats

Medical Developments International Ltd should also be aware of potential threats that could hinder its growth:

  • Intense competition: The healthcare industry is highly competitive, and the company faces the risk of losing market share to competitors.
  • Regulatory challenges: Stringent regulations and compliance requirements in the healthcare sector can pose barriers to market entry or product development.
  • Economic downturns: Economic uncertainties or recessions may affect customer spending capacity and reduce demand for medical solutions.

Medical Developments International Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Medical Developments International historical P/E ratio, EBIT multiple, and P/S ratio

Medical Developments International annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medical Developments International shares outstanding

The number of shares of Medical Developments International was 112.16 M in 2025. This indicates how many shares Medical Developments International is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
71.42 M Stocks
Jan 1, 2022
73.17 M Stocks
Jan 1, 2023
86.52 M Stocks
Jan 1, 2024
88.60 M Stocks
Jan 1, 2025
112.16 M Stocks
Jan 1, 2026 (e)
112.16 M Stocks
Jan 1, 2027 (e)
112.16 M Stocks
Jan 1, 2028 (e)
112.16 M Stocks

Medical Developments International Dividend History

10 years of dividend payments

YearAnnual DividendYoY ChangePayments
20200.03AUD↓ 50.0%1×
20190.06AUD↓ 1.8%2×
20180.06AUD↓ 1.7%2×
20170.06AUD 0.0%2×
20160.06AUD↑ 103.2%2×
20140.03AUD↓ 60.6%—
20130.07AUD↓ 16.7%2×
20120.09AUD↑ 100.0%2×
20110.04AUD↑ 1,100.0%1×
20040.00AUD—1×

Medical Developments International dividend payout ratio

In 2025, Medical Developments International had a payout ratio of 563.36%. The payout ratio indicates the percentage of the company's profits that Medical Developments International distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
723.34 %
Jan 1, 2022
515.15 %
Jan 1, 2023
571.59 %
Jan 1, 2024
603.36 %
Jan 1, 2025
563.36 %
Jan 1, 2026 (e)
579.44 %
Jan 1, 2027 (e)
582.05 %
Jan 1, 2028 (e)
142.97 %

Current Medical Developments International forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.18 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
0.86
Last Price
0.48
Currency
AUD
12M Return Potential
78.50 %
LTM Return
0 %

Medical Developments International Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/20/20200.00AUD-12.64 MAUD-2020 Q4

EESG©

Eulerpool ESG Scorecard© for the Medical Developments International stock

15/100
17
Environment
11
Social
17
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medical Developments International shareholder structure

% Name
2.59840%
FIL Investment Management (Hong Kong) Limited
FIL Investment Management (Hong Kong) Limited
0.05883%
DFA Australia Ltd.
DFA Australia Ltd.

Medical Developments International Executives and Management Board

8 members · avg. age 59 · 38 % women

BM

Mr. Brent Macgregor

Chief Executive Officer

1.94 M AUD

Management

AJ

Ms. Anita James

Chief Financial Officer

505,609.00 AUD
TE

Ms. Tara Eaton

Company Secretary

–

Board of Directors

GN

Mr. Gordon Naylor (59)

Non-Executive Chairman of the Board

95,000.00 AUD
RB

Mr. Richard Betts

Non-Executive Director

60,000.00 AUD
CE

Ms. Christine Emmanuel-Donnelly

Non-Executive Independent Director

60,000.00 AUD
LH

Mr. Leon Hoare

Non-Executive Independent Director

60,000.00 AUD
RB

Dr. Russell Basser

Director

50,000.00 AUD

Medical Developments International Supply Chain

Medical Developments International Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#NameTrend
1
Covetrus Inc
Customer·Health Care Providers & Services·US
-0.49
-0.68
0.01
0.54
0.22
0.60
#NameTrend
1
AmerisourceBergen
Customer·Health Care Providers & Services·US
-0.12
-0.01
-0.07
-0.81
-0.63
-0.80
2
HSBC Holdings
Supplier·Customer·Banks·GB
-0.30
0.55
0.10
-0.74
-0.53
-0.61
3
M&G
Supplier·Customer·Diversified Financial Services·GB
-0.35
0.24
0.05
-0.46
-0.27
-0.49
4
JPMorgan Chase
Supplier·Customer·Banks·US
-0.62
0.29
0.71
0.88
0.78
-0.37
5
Walmart
Customer·Food & Staples Retailing·US
0.80
0.47
-0.69
-0.49
-0.38
-0.35

Frequently asked questions about Medical Developments International

The business model of Medical Developments International Ltd is focused on developing and commercializing innovative pharmaceutical products. With a strong emphasis on research and development, the company aims to improve healthcare by offering safe and effective medical solutions. Medical Developments International Ltd strives to collaborate with healthcare professionals and institutions to deliver high-quality and affordable medical products. Through its commitment to innovation and partnership, the company has established itself as a leading player in the healthcare industry, continuously working towards improving patient outcomes and overall healthcare delivery.

Medical Developments International Ltd primarily operates in the healthcare industry.

The main competitors of Medical Developments International Ltd in the market include companies such as Pfizer, Johnson & Johnson, and GlaxoSmithKline.

Medical Developments International Ltd is a leading Australian pharmaceutical company specializing in the development and distribution of innovative medical devices and drugs. Founded in 1971, Medical Developments International Ltd has consistently demonstrated a commitment to improving patient outcomes through advanced healthcare products. With a strong focus on research and development, the company has successfully introduced breakthrough solutions in the areas of pain management, respiratory care, and emergency medicine. Over the years, Medical Developments International Ltd has garnered a solid reputation for delivering high-quality and effective medical solutions to healthcare professionals worldwide.

Medical Developments International Ltd has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative medical solutions, positioning itself as a global leader in emergency medical products. Notably, Medical Developments International Ltd has received regulatory approvals for their flagship product, Penthrox, across various countries, including the EU, UK, Australia, New Zealand, and Canada. The company has also forged partnerships with renowned distributors, enabling them to expand their market presence and increase sales. Additionally, Medical Developments International Ltd has continuously invested in research and development to enhance their product portfolio, ensuring they remain at the forefront of medical advancements.

Medical Developments International Ltd (MDI) is primarily present in several countries and regions. The company has a global footprint with significant operations in Australia, New Zealand, and the United States. As an internationally recognized healthcare company, MDI caters to a wide range of markets worldwide, including Europe, Asia, and the Middle East. With its innovative medical solutions and strong market presence, Medical Developments International Ltd continues to expand its reach to meet the growing demand for its products and services across various countries and regions.

Medical Developments International Ltd represents the values of innovation, patient care, and commitment to excellence. With a corporate philosophy centered around improving health outcomes, they strive to develop and provide high-quality medical solutions. By continually researching and investing in cutting-edge technology, Medical Developments International Ltd aims to revolutionize healthcare and create effective treatments for various conditions. Their commitment to integrity, accountability, and ethical practices makes them a trusted leader in the industry. With a focus on improving the well-being of patients, Medical Developments International Ltd is dedicated to delivering innovative solutions that enhance the quality of life for individuals worldwide.

Analysts currently set an average price target of 0.86 AUD for the Medical Developments International stock (median: 0.86 AUD), implying +78.5 % versus the latest price. The consensus is based on 5 analyst ratings.

Medical Developments International Analyst Price Targets 2026

5 analysts currently rate the Medical Developments International stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Medical Developments International to generate revenue of 46.46 M AUD and earnings per share of -0.02 AUD.

Medical Developments International Analyst Price Targets 2026

Converted at the current exchange rate, the Medical Developments International share trades at 0.29 EUR (0.48 AUD).

The Medical Developments International share (MVP.AX) is listed on 2 stock exchanges, including: ASX (MVP.AX).

Medical Developments International Ltd is an Australian company that offers sustainable solutions in the field of lifesaving, pain relief, and inhalation therapy. The company develops, manufactures, and distributes inhalers, pain relief products, and medical devices. In the lifesaving sector, the company offers the emergency inhalator system Penthrox. This system is used in the treatment of acute pain and injuries such as bone fractures and burns. The Penthrox system is easy to handle and can be quickly deployed by paramedics and emergency physicians on site. This technology is ideal for the military, sports events, and other public gatherings. The company also offers a wide range of pain relief products. The pain reliever Green whistle is a sustainable, hydrogen-based analgesic used in pain therapy. It is easy to use, safe, and effective. The device is ideal for use in hospitals, pain therapy, and palliative care. Inhalation therapy is the company's third business area. The company offers a wide range of inhalation devices specifically developed for people with asthma or other respiratory diseases. With the nebulizer "Nebu-Tech," patients receive precise dosage of the medication, which effectively reaches the lungs. The company has also developed solutions for kindergarten and school medicine to improve the treatment of children and students with asthma. Medical Developments International Ltd places special emphasis on sustainability and environmental friendliness. The company invests in research and development of sustainable technologies and materials to provide eco-friendly products and services. The products are designed for long-term use and can be easily recycled. The well-being of the patient is also a priority in production. No animal components are used, and high standards of quality and safety are ensured. In summary, Medical Developments International Ltd offers a wide range of products that can be used to save lives, alleviate pain, and treat respiratory diseases. The company is focused on sustainability and environmental friendliness and places special emphasis on quality and safety. With the marketing of high-quality products, the company aims to improve the lives of its customers.

The expected revenue of Medical Developments International is 46.46 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medical Developments International is -2.04 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medical Developments International is currently -26.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medical Developments International stock.

The price-to-sales ratio (P/S) of Medical Developments International is currently 1.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medical Developments International stock.

The Eulerpool Quality Score for Medical Developments International is 2/10.

The ISIN of Medical Developments International is AU000000MVP2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medical Developments International is A0BLXB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medical Developments International is MVP.AX. The ticker symbol is used to trade Medical Developments International shares on the stock exchange.

Over the past 12 months, Medical Developments International paid a dividend of 0.03 AUD . This corresponds to a dividend yield of about 5.75 %. For the coming 12 months, Medical Developments International is expected to pay a dividend of 0.05 AUD.

The current dividend yield of Medical Developments International is 5.75 %.

Medical Developments International pays a dividend, distributed in the months of , , , .

Medical Developments International paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.05 AUD are expected. This corresponds to a dividend yield of 11.31 %.

Medical Developments International is assigned to the 'Health' sector.

To receive the latest dividend of Medical Developments International from amounting to 0.03 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Medical Developments International are distributed in AUD.

All fundamentals and in-depth analysis of Medical Developments International

Our stock analysis for Medical Developments International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medical Developments International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Medical Developments International Stock
Medical Developments International Revenue→
Medical Developments International Stock
Medical Developments International Net Income→
Medical Developments International Stock
Medical Developments International P/E→
Medical Developments International Stock
Medical Developments International P/S→
Medical Developments International Stock
Medical Developments International EBIT→
Medical Developments International Stock
Medical Developments International Dividend→
Medical Developments International Stock
Medical Developments International Directors Dealings→
Medical Developments International Stock
Medical Developments International Stocks→
Medical Developments International Stock
Medical Developments International Market capitalization→
Medical Developments International Stock
Medical Developments International Debt→
Medical Developments International Stock
Medical Developments International Liabilities→
Medical Developments International Stock
Medical Developments International Equity→
Medical Developments International Stock
Medical Developments International AAQS→
Medical Developments International Stock
Medical Developments International Employees→
Medical Developments International Stock
Medical Developments International ROE→
Medical Developments International Stock
Medical Developments International ROA→
Medical Developments International Stock
Medical Developments International ROCE→
Medical Developments International Stock
Medical Developments International News→
Medical Developments International Stock
Medical Developments International Analyst Price Targets→

Health Stocks

Medical ImagingMedical Connections HoldingsMedical International TechnologyMedical Care TechnologiesMedical MarijuanaMedica Sur SAB de CVMedicalgorithmicsMediana CoMedicalSystem Biotechnology CoMedian TechnologiesMedicamen BiotechMedi Assist Healthcare ServicesAll Stocks A–Z →